UNSPSC 51372024: Cyprenorphine hydrochloride

This classification denotes the hydrochloride form of an opioid receptor agonist with the molecular formula C26H33NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1P6HEG5ZHS, chemically known as 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-4,5-epoxy-3-hydroxy-6-methoxy-alpha,alpha-dimethyl-, (5alpha,7alpha)- but more generally known as cyprenorphine, which bears US NIH Compound Identifier 20435.

UNSPSC 51372024 Cyprenorphine hydrochloride is a Commodity code for a pharmaceutical substance used in opioid-dependence treatment and pain management, though state and local government procurement activity under this specific code shows minimal recent documented volume. The single recent opportunity on record—Seminole County, Florida's IFB for naloxone and drug deactivation systems—is tangential to cyprenorphine itself and appears to reflect misclassification or a county's broad pharmaceutical-procurement tagging practice rather than direct sourcing of this substance.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The contract includes a two-year initial term with one-year renewal option, fixed-fee pricing, E-Verify compliance, and potential FEMA funding. Beyond this single record, no other state or local opportunities under this code appear in recent activity, suggesting that cyprenorphine procurement either routes through other UNSPSC categories (such as broader pharmaceutical codes or opioid-specific classifications), is consolidated under multi-drug master agreements, or remains inactive at the state and local level. Practitioners should verify whether procurement for this substance is tagged differently across jurisdictions or whether demand is concentrated in federal healthcare systems and specialized opioid-treatment networks outside typical state and local competitive channels.